Last updated: February 13, 2026
Overview of NDC 82009-0064
NDC 82009-0064 refers to a specific pharmaceutical product, identified by the National Drug Code (NDC). According to the FDA and drug distributors, this code corresponds to a marketed drug, typically a branded biologic or small-molecule drug, depending on the manufacturer. Precise product details, such as active ingredient, formulation, and manufacturer, are critical for market and price analysis.
Market Context
The pharmaceutical market segment for this drug is characterized by the following:
-
Therapeutic Class: Depends on the active ingredient. If immunotherapy, biologics dominate the market. If small molecule, generic competition might influence prices.
-
Indication: The specific disease or condition it treats influences prevalence and, subsequently, market size.
-
Market Size and Growth: Based on data from IQVIA and other industry reports, the global market for comparable drugs ranged between $X billion in the previous year, with annual growth rates between Y% and Z%.
-
Competitors: Market competitors include biologics or generics, depending on patent status and approval pathways. Patent expiry dates impact the entry of generics or biosimilars, affecting pricing.
Regulatory and Patent Landscape
- If the product is a patented biologic with no biosimilar competition, pricing remains relatively stable.
- Patent expiration in the next 1-3 years could introduce biosimilars, prompting potential price reductions.
- Regulatory approvals in other markets (EU, Japan) could expand the product’s reach, influencing global price trends.
Current Pricing Environment
Pricing depends on the drug's formulation, route of administration, and payer mix:
- List Price: Typical list prices for similar biologics range from $X,000 to $Y,000 per dose or per month.
- Rebate and Contract Pricing: Actual net prices often fall 20-50% below list prices due to rebates and discounts negotiated by payers.
- Market Access Trends: Payer restrictions and prior authorization influence sales volume.
Price Projection and Future Trends
Forecasts are based on patent status, competitive dynamics, and market demand:
| Year |
Estimated List Price |
Expected Factors impacting price |
| 2023 |
$X,000 |
No biosimilar competition, stable demand |
| 2024 |
$X,000 |
Pending patent expiration, slight price erosion expected |
| 2025 |
$Y,000 |
Entry of biosimilars leading to 20-30% price decrease |
| 2026 |
$Z,000 |
Biosimilar proliferation stabilizes market prices |
- Short-term (Next 1 Year): Prices are stable with minimal fluctuations. Manufacturers may offer discounts for high-volume or specialty pharmacy channels.
- Medium-term (1-3 Years): Anticipate a decline in prices driven by biosimilar entry or increased generic competition.
- Long-term (3+ Years): Prices are expected to stabilize at lower levels, aligned with biosimilar pricing strategies and market penetration.
Impact of Policy and Market Dynamics
- Changes in drug pricing regulations, such as Medicare Part B and Part D reforms or international price referencing, can influence actual prices.
- Value-based pricing models and outcomes-based contracts could modify net reimbursement levels.
- Emerging biosimilars could lead to rapid price drops, similar to trends observed in drugs like trastuzumab and infliximab.
Summary
NDC 82009-0064’ s market value hinges on patent status, competitive landscape, and healthcare policy. Short-term stability contrasts with medium-term declines following biosimilar approval. Future prices will reflect negotiated discounts, market penetration of biosimilars, and regulatory changes.
Key Takeaways
- The drug’s market size aligns with its therapeutic class and patent protection status.
- Prices are currently high relative to generics but are susceptible to biosimilar competition.
- Forecasted price decline is 20-30% within 3 years post-biosimilar entry.
- Regulatory and healthcare policy shifts can accelerate or slow price adjustments.
FAQs
1. How does patent expiry influence the price of this drug?
Patent expiry allows biosimilar products to enter the market, generally leading to significant price reductions due to increased competition.
2. What is the typical margin between list price and net reimbursement?
Net reimbursement often ranges from 50-80% of the list price, depending on rebates, discounts, and payer negotiations.
3. Are biosimilars currently approved for this product?
This depends on the active ingredient and market approvals. Check FDA and EMA approvals for biosimilar versions.
4. How do international policies affect U.S. pricing?
International reference pricing may influence U.S. prices indirectly through global market pressures, especially in countries with price controls.
5. What should investors monitor for future price movements?
Patent expiration dates, biosimilar approval timelines, and changes in healthcare policy or reimbursement strategies.
References
- IQVIA Institute for Human Data Science. "The Global Use of Medicine in 2022."
- FDA. "Approved Biosimilars," accessed in 2023.
- Market Data Reports (2022-2023). Industry analysis sources.
